LAG-3: The next big checkpoint inhibitor target
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in…
November 29, 2022 - 7 minutes
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in…
Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002…
This week, we have three guests. We have conversations with Marc Voigt, CEO of Immutep;…
Immutep Limited says the United States Food and Drug Administration (FDA) has granted fast track…
Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease,…